Corporate Overview
| Company Name | Solasia Pharma K.K. |
|---|---|
| Address | 4F SUMITOMO FUDOSAN SHIBA-KOEN TOWER, 2-11-1 Shiba-koen, Minato-ku, Tokyo 105-0011 Japan |
| Phone Number | +81 3 5843 8045 |
| Date of Establishment | December 2006 |
| President & CEO | Yoshihiro Arai |
| Scope of Business | Development, marketing, import/export of pharmaceutical products and medical devices, etc. |
| Access |
Direction By Train JR “Hamamatsucho Station” Kanasugibashi Exit, 7 minutes walk Toei Subway Mita Line “Shiba-koen Station” A3 Exit, 2 minutes walk |
Subsidiary Company (Wholly Owned)
| Company Name | 苏爱康医药信息咨询（上海）有限公司 Solasia Medical Information Consulting (Shanghai) Co. Ltd. Website |
|---|---|
| [ Main Office/Shanghai Office ] | |
| Address | 上海市浦东新区世纪大道826号陆家嘴金融广场18层03单元 Unit03, 18F, Lujiazui Finance Plaza, No. 826 Century Avenue, Pudong, Shanghai ,China 200120 |
| Phone Number | +86-21-5116-7129 |
| [ Beijing Office ] | |
| Address | 北京市朝阳区朝阳门外大街甲六号万通中心D座3层 3Floor, Tower D, Vantone Center, No.6 Chaoyangmenwai Street, Chaoyang District ,Beijing, China 100022 |
| Phone Number | +86-10-5907-0408 |
| [ Guangzhou Office ] | |
History/Timeline
| Aug 2022 | Launched DARVIAS Injection 135mg (generic name: DARINAPARSIN /development code: SP-02) in Japan |
|---|---|
| Aug 2022 | License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso and episil in three cities in China |
| Jul 2022 | Solasia acquires episil® world wide business rights from Camurus |
| Apr 2022 | Solasia listed it’s shares on Tokyo Stock Exchange, Growth |
| Oct 2021 | License Agreement with Nippon Kayaku Co., Ltd. for commercialization of darinaparsin (SP-02) in Japan |
| Sep 2020 | Launched episil® (SP-03) in South Korea |
| Aug 2020 | License Agreement with Isofol Medical AB for exclusive license of arfolitixorin (SP-05) in Japan |
| Jan 2020 | License Agreement with Synex for commercialization of episil® (SP-03) in South Korea |
| Dec 2019 | License Agreement with Maruho Co., Ltd. for commercialization of PledOx® (SP-04) in Japan |
| Oct 2019 | Obtained Commercial Approval of episil® (SP-03) in South Korea |
| Jul 2019 | Launched episil® (SP-03) in China |
| Mar 2019 | Launched Sancuso® (SP-01) in China |
| Feb 2019 | Obtained Approval of episil® (SP-03) in China as new medical device |
| Aug 2018 | License and Distribution Agreement with HB Human BioScience SAS for exclusive license of darinaparsin (SP-02) in Latin America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala) |
| Aug 2018 | License and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in South Korea |
| Jul 2018 | Obtained Approval of Sancuso® (SP-01) in China |
| Nov 2017 | License Agreement with PledPharma AB (currently Egetis Therapeutics AB) for exclusive license of PledOx® (SP-04) in Japan, China and other Asian territories |
| Jul 2017 | Obtained Approval of episil® (SP-03) in Japan as new medical device |
| Mar 2017 | Solasia listed it’s shares on Tokyo Stock Exchange, Mothers |
| Feb 2017 | License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of episil® (SP-03) in China excluding Beijing, Shanghai, Guangzhou and Taiwan |
| Nov 2016 | License and Collaboration Agreement with Meiji Seika Pharma for episil® (SP-03) in Japan |
| Nov 2015 | License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of Sancuso® (SP-01) in China excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau and Taiwan |
| Mar 2015 | Licensed and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in Japan and China |
| Dec 2014 | Establishment of the subsidiary in Shanghai |
| Jul 2014 | License Agreement with ZIOPHARM Oncology Inc. (currently Alaunos Therapeutics) for global license and collaboration for darinaparsin (SP-02) |
| Dec 2011 | Open Beijing Representative Office in China |
| Mar 2011 | License Agreement with ZIOPHARM Oncology Inc. (currently Alaunos Therapeutics) for exclusive rights to darinaparsin (SP-02) in Japan, China, and other Asian territories |
| Feb 2010 | License Agreement with Kyowa Hakko Kirin Co., Ltd. (currently Kyowa Kirin) for the sublicense of Sancuso® (SP-01) in Taiwan, Hong Kong, Singapore & Malaysia |
| Sep 2008 | Company name changed to Solasia Pharma K.K. |
| May 2008 | License Agreement with ProStrakan (currently Kyowa Kirin Services Limited) for exclusive rights to Sancuso® (SP-01) in Japan, China, and other Asian territories |
| Dec 2006 | Business started as JapanBridge in the United States with investments by MPM Capital, US and ITOCHU Corporation, JP |